Molecular Partners Ag (MOLN) Net Income (2020 - 2026)
Molecular Partners Ag's (MOLN) quarterly Net Income came in at -$17.2 million in Q2 2026, up 30.33% year-over-year from -$13.2 million in Q2 2025, and down 2.22% quarter-over-quarter from -$16.8 million in Q1 2026.
Analysis
Molecular Partners Ag (MOLN) Net Income (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Net Income for 7 consecutive years, with -$17.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Income rose 30.33% year-over-year to -$17.2 million in Q2 2026; TTM through Jun 2026 was -$64.6 million, a 13.96% increase from a year earlier, with the FY2025 full-year figure at -$74.4 million, down 21.05% from the prior year.
- Net Income was -$17.2 million for Q2 2026 at Molecular Partners Ag, down from -$16.8 million in the prior quarter.
- Over five years, Net Income peaked at $165.8 million in Q1 2022 and troughed at -$24.6 million in Q2 2025.
- A 5-year average of -$6.1 million and a median of -$16.3 million in 2023 frame the typical range for Net Income.
- Across the five-year window, Net Income jumped 1005.54% in 2022 and slumped 279.18% in 2023, its largest moves.
- Over 5 years, Net Income stood at -$18.1 million in 2022, then decreased by 23.22% to -$22.3 million in 2023, then jumped by 42.52% to -$12.8 million in 2024, then fell by 23.43% to -$15.8 million in 2025, then fell by 8.56% to -$17.2 million in 2026.
- The last three Net Income figures came in at -$17.2 million (Q2 2026), -$16.8 million (Q1 2026), and -$15.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | -17.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.16 Mn |
| Mar 31, 2026 | -16.79 Mn |
| Dec 31, 2025 | -15.81 Mn |
| Sep 30, 2025 | -14.80 Mn |
| Jun 30, 2025 | -24.64 Mn |
| Mar 31, 2025 | -18.66 Mn |
| Dec 31, 2024 | -12.81 Mn |
| Sep 30, 2024 | -18.94 Mn |
| Jun 30, 2024 | -16.68 Mn |
| Mar 31, 2024 | -12.98 Mn |
| Dec 31, 2023 | -22.29 Mn |
| Sep 30, 2023 | -12.96 Mn |
| Jun 30, 2023 | -17.78 Mn |
| Mar 31, 2023 | -15.98 Mn |
| Dec 31, 2022 | -18.09 Mn |
| Sep 30, 2022 | -13.80 Mn |
| Jun 30, 2022 | -4.69 Mn |
| Mar 31, 2022 | 165.80 Mn |
| Dec 31, 2021 | -19.41 Mn |
| Sep 30, 2021 | -13.41 Mn |